No published human studies have shown that CJC-1295 causes cancer. However, this is not the same as saying the question has been thoroughly investigated and ruled out. The accurate picture is more complex. There is a plausible biological concern based on the general physiology of growth hormone and IGF-1. Direct data on cancer outcomes specifically for CJC-1295 simply do not exist in the peer-reviewed literature searched for this series, however. This distinction between „lack of evidence of harm” and „proven safety” is critical for such a serious question and is treated with appropriate caution here.
Does CJC-1295 cause cancer?
No clinical trials, case-control studies, or long-term cohort studies identified in the peer-reviewed literature directly measure cancer incidence in individuals using CJC-1295. This means the article cannot provide direct evidence in humans that either confirms or excludes cancer risk from this specific compound.
What actually exists is a legitimate, general concern rooted in well-established endocrinology. IGF-1 – the hormone that CJC-1295 is specifically designed to raise – is recognized in mainstream medical science for having growth-stimulating, or „mitogenic,” effects on cells. This means it can stimulate cell division and proliferation as part of its normal biological role in the body. This is the fundamental reason why IGF-1 and the broader growth hormone–IGF-1 axis have long been an area of general research interest within oncology. Aberrant or excessive cell growth signaling is relevant to how certain cancers develop and progress.
Reflecting this, a 2026 review specifically covering performance-enhancing peptides acting on the growth hormone–IGF-1 axis, including CJC-1295, described „biologically plausible but unproven mitogenic concerns” as part of the safety profile for this class of compounds [1]. This is an accurate and appropriately cautious way to capture where science stands currently. The concern is real and rooted in known biology. However, it remains unproven and theoretical specifically for CJC-1295, rather than demonstrated by any direct study measuring actual cancer outcomes in individuals who have used it.
Taking this into account, it would be inaccurate to state either that CJC-1295 „causes cancer”—which is not supported by any direct evidence—or that it is „cancer-safe”—which is also not something current research can confirm. The accurate position is this: a theoretical concern exists and remains unsettled, due to a lack of dedicated long-term human studies.
Heart attack risk with CJC-1295 – what the studies show
No published clinical studies identified in the reviewed literature for this series specifically measured the incidence of myocardial infarction, cardiovascular events, or long-term cardiac outcomes in individuals using CJC-1295. Therefore, no direct evidence is available, either supporting or refuting cardiovascular risk specific to this compound.
Short-term human studies that exist for CJC-1295 were designed to measure hormonal responses – growth hormone and IGF-1 levels – over a period of several weeks. They reported no serious adverse reactions within that timeframe. However, cardiovascular-specific safety analysis was not a primary focus of these studies and was not detailed in the reporting [2].
It's important to clearly state this. The absence of a reported cardiac event during a short, small hormonal response study is reassuring as far as it goes. However, it is not equivalent to a dedicated cardiovascular safety study. Nor does it address what might happen with longer use or higher doses outside of monitored clinical conditions.
Broader reviews of growth hormone axis-modulating peptides as a category have noted endocrine and metabolic disturbances—including effects on blood glucose regulation—as part of the recognized adverse effect profile for this drug class. Metabolic disturbances of this nature are generally relevant to cardiovascular health in general medicine. While this represents a general observation at the category level, rather than a specific, confirmed finding of cardiac risk for CJC-1295 itself [1].
Given the complete lack of dedicated cardiovascular outcome studies for this specific compound, no evidence-based claim can be made regarding the risk of myocardial infarction in either direction. This remains an open question requiring further investigation, not a settled one.
Long-term side effects of CJC-1295
There are currently no published studies analyzing the effects of using CJC-1295 for months or years. This means that the long-term side effects remain truly unknown, rather than just unlikely or well-characterized.
The human studies that generated the main safety data cited throughout this series were short-term. The main CJC-1295 study lasted for periods of 28 and 49 days. It was also conducted on a small number of healthy adult volunteers under direct clinical supervision – a very different scenario from prolonged, unsupervised use over an extended period [2].
Many recent scientific reviews covering this broader category of growth hormone secretagogues have explicitly acknowledged this gap. They state outright that rigorous, long-term safety data in humans remains scarce for these unapproved compounds, and that the true potential for harm exists precisely because this long-term picture has not been established [1], [3].
Limitations of current evidence
Regarding cancer risk, cardiovascular risk, and long-term side effects, the pattern is the same. Available short-term clinical studies for CJC-1295 have not identified serious adverse events. However, none were designed or large enough to detect rare, delayed, or long-latency outcomes such as cancer or cardiovascular disease. These typically require years of follow-up in much larger populations to properly assess.
The theoretical concern surrounding IGF-1's growth-promoting effects is rooted in real, established biology. However, it remains a theoretical concern for this particular compound, rather than a demonstrated risk. The same applies to cardiovascular safety. This is a significant and sound limitation of the current evidence base – not a minor caveat.
Disclaimer
This content is for educational and informational purposes only. It should not be interpreted as medical advice, diagnosis, or a guarantee of safety. CJC-1295 remains a research compound and is not approved by the FDA or the European Medicines Agency for any medical use. No published human studies have measured cancer incidence, cardiovascular events, or long-term health outcomes specifically for this compound, meaning these risks remain unanswered questions rather than established facts either way. Anyone with a personal or family history of cancer, cardiovascular disease, or other serious medical conditions should discuss any consideration of research peptides with a qualified healthcare professional prior to use.
Dominikowski, A., Rękoś, Z., Olejarz, M., Szczepanek-Parulska, E., Domin, R., & Ruchała, M. (2026). The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: Bridging the gap between clinical evidence and patient self-administration. Frontiers in Endocrinology, 17, Article 1822475. https://doi.org/10.3389/fendo.2026.1822475
[2] Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
[3] Mendias, C. L., & Awan, T. M. (2026). Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Medicine. Advance online publication. https://doi.org/10.1007/s40279-026-02437-0